<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264628</url>
  </required_header>
  <id_info>
    <org_study_id>SND103929</org_study_id>
    <nct_id>NCT00264628</nct_id>
  </id_info>
  <brief_title>GW679769 In Fibromyalgia</brief_title>
  <official_title>An Outpatient, Randomised, Double-blind, Placebo Controlled, Parallel Group Exploratory Study to Evaluate Safety, Tolerability and Efficacy of GW679769 in Patients With Fibromyalgia Syndrome Comorbid With Depression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate safety, tolerability and efficacy of oral GW679769
      up to 120 mg dose compared to placebo in patients with ACR(American College of
      Rheumatology)-defined fibromyalgia, co-morbid with depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Change in Fibromyalgia Impact Questionnaire (FIQ) total score</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of GW679769 vs placebo in health-related quality of life outcomes</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between PK of GW679769 and clinical outcome in patients</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Depression</condition>
  <condition>Fibromyalgia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW679769</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of fibromyalgia (ACR criteria).

          -  Non-severe depression (HAM-D score &gt;14 &lt;24).

          -  Women must commit to consistent use of an acceptable method of birth control.

        Exclusion criteria:

          -  Severe depression (HAM-D score &gt; 24).

          -  Unable to discontinue medications for pain or depression.

          -  Laboratory and ECG value at screening outside sponsor defined ranges.

          -  Positive to stool occult blood test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NK1-antagonist</keyword>
  <keyword>Depression</keyword>
  <keyword>Fibromyalgia</keyword>
  <keyword>GW679769</keyword>
  <keyword>Outpatient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Casopitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

